FDA Approval Summary: Idecabtagene Vicleucel for Relapsed or Refractory Multiple Myeloma.
Saved in:
| Title: | FDA Approval Summary: Idecabtagene Vicleucel for Relapsed or Refractory Multiple Myeloma. |
|---|---|
| Authors: | Sharma P; Center for Biologics Evaluation and Research, Silver Spring, Maryland., Kanapuru B; Center for Drug Evaluation and Research, Silver Spring, Maryland.; Oncology Center of Excellence, U.S. Food and Drug Administration, Silver Spring, Maryland., George B; Center for Biologics Evaluation and Research, Silver Spring, Maryland., Lin X; Center for Biologics Evaluation and Research, Silver Spring, Maryland., Xu Z; Center for Biologics Evaluation and Research, Silver Spring, Maryland., Bryan WW; Center for Biologics Evaluation and Research, Silver Spring, Maryland., Pazdur R; Center for Drug Evaluation and Research, Silver Spring, Maryland.; Oncology Center of Excellence, U.S. Food and Drug Administration, Silver Spring, Maryland., Theoret MR; Center for Drug Evaluation and Research, Silver Spring, Maryland.; Oncology Center of Excellence, U.S. Food and Drug Administration, Silver Spring, Maryland. |
| Source: | Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2022 May 02; Vol. 28 (9), pp. 1759-1764. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: American Association for Cancer Research Country of Publication: United States NLM ID: 9502500 Publication Model: Print Cited Medium: Internet ISSN: 1557-3265 (Electronic) Linking ISSN: 10780432 NLM ISO Abbreviation: Clin Cancer Res Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
